Skip to main content

NICE TAs

13/06/2024
TA982: Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over
05/06/2024
TA979: Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation
08/05/2024
TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19
08/05/2024
TA970: Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments
28/03/2024
TA962: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
27/03/2024
TA959: Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis
27/03/2024
TA958: Ritlecitinib for treating severe alopecia areata in people 12 years and over
21/02/2024
TA952: Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations
13/12/2023
TA939: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
22/11/2023
TA931: Zanubrutinib for treating chronic lymphocytic leukaemia
11/10/2023
TA918: Bimekizumab for treating axial spondyloarthritis
15/08/2023
TA912: Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease
28/04/2022
TA787: Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
28/04/2022
TA786: Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies
11/10/2021
TA704: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies
11/10/2021
TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer
11/10/2021
TA706: Ozanimod for treating relapsing–remitting multiple sclerosis
11/10/2021
TA707: Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer
11/10/2021
TA708: Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis
11/10/2021
TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome
Follow AWTTC: